Ultrahypofractionated radiotherapy in one or two sessions for localized prostate cancer: a review of the evidence and future perspectives
Clinical and Translational Oncology · 2025
DOI: 10.1007/s12094-025-04041-6 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical and Translational Oncology, 2025. Verfasst von Miguel Angel Berenguer-Frances und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Vithas Consuelo Hospital, Genesis Care, Valencia, 46007, Spain. migberenguer@hotmail.com. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Radiosurgery, Brachytherapy, Radiation Dose Hypofractionation. Die Arbeit nennt 31 Literaturangaben.
Abstract (Originalsprache)
This narrative review analyzes current evidence comparing single-session and two-session approaches in Stereotactic Body Radiation Therapy (SBRT) and high-dose-rate (HDR) brachytherapy for localized prostate cancer. These ultra-hypofractionated strategies deliver high-precision ablative doses while minimizing exposure to normal tissues. SBRT regimens with fewer than five fractions show tumor control comparable to conventional treatments, offering reduced treatment burden and increased convenience. While single-dose outcomes are often suboptimal, two-fraction regimens-especially in HDR brachytherapy-are widely used and may better preserve normal tissues and reduce toxicity. Studies utilizing advanced imaging, real-time motion management, and adaptive planning improve treatment accuracy. Two-session approaches appear safe and effective in the short to intermediate term, though long-term data for single-session SBRT remain limited. The review emphasizes tailoring treatment based on patient factors, tumor characteristics, and institutional capabilities, and calls for further research to refine ultra-hypofractionated radiotherapy protocols for prostate cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, Vithas Consuelo Hospital, Genesis Care, Valencia, 46007, Spain. migberenguer@hotmail.com.
- Department of Radiation Oncology, La Fe Hospital, Valencia, 46206, Spain. migberenguer@hotmail.com.
- Department of Radiation Oncology, San Francisco de Asís University Hospital, Genesis Care, Madrid, 28002, Spain.
- Geneva University Hospital, Geneva University Hospital, Geneva, Switzerland.
- Faculty of Medicine, University of Geneva, Geneva, Switzerland.
- Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland.
Zitieren
APA
Berenguer-Frances, M. A., Ocanto, A., Zilli, T., Lopez-Campos, F., Celada, F., Gomez-Iturriaga, A., Tree, A., Arcangeli, S., & Couñago, F. (2025). Ultrahypofractionated radiotherapy in one or two sessions for localized prostate cancer: a review of the evidence and future perspectives. Clinical and Translational Oncology. https://doi.org/10.1007/s12094-025-04041-6
Vancouver
Berenguer-Frances MA, Ocanto A, Zilli T, Lopez-Campos F, Celada F, Gomez-Iturriaga A, et al. Ultrahypofractionated radiotherapy in one or two sessions for localized prostate cancer: a review of the evidence and future perspectives. Clinical and Translational Oncology. 2025. doi:10.1007/s12094-025-04041-6
BibTeX
@article{BerenguerFrances2025,
author = {Berenguer-Frances, Miguel Angel and Ocanto, Abrahams and Zilli, Thomas and Lopez-Campos, Fernando and Celada, Francisco and Gomez-Iturriaga, Alfonso and Tree, Alison and Arcangeli, Stefano and Couñago, Felipe},
title = {Ultrahypofractionated radiotherapy in one or two sessions for localized prostate cancer: a review of the evidence and future perspectives},
journal = {Clinical and Translational Oncology},
year = {2025},
doi = {10.1007/s12094-025-04041-6}
}
EUVIMED